Stille AB: Interim Report Q3 2022
Stille AB (publ) publishes the interim report for the third quarter of 2022. ”The first three quarters of this year has displayed significant growth coupled with solid profitability. The third quarter continued the positive trend achieved during previous quarters this year”, says Hanna Ernestam Wilkman, Stille’s CEO.
Revenues increased by 17 percent to 59.6 MSEK (51.1). Operating profit increased by 32 percent to 7.2 MSEK (5.5). Positive currency effects of 2.7 MSEK affected the result after financial items.
Revenues for Surgical Instruments increased by six percent to 30.1 MSEK (28.4). Profitability was affected by an unfavorable product and geographic market mix. Surgical Table-revenues grew by 30 percent to 29.5 MSEK (22.7). Sales have been particularly strong in EMEA with a growth of 47 percent.
The challenging environment, primarily with disturbances in supply chains, has affected Stille during the quarter. This has however not affected sales. The challenges are expected to continue going forward.
”The long waiting lists for elective surgery remains and must be addressed regardless. Stille contributes with premium products enabling maximal efficiency. With market leading brands, and cost-control, Stille stands well-prepared for the future", concludes Hanna Ernestam Wilkman.
|Gross Profit Margin, %||45.1||45.0||45.1||44.2||45.5||44.6|
|Operating Profit, %||12.1||10.7||12.8||11.4||12.1||10.7|
Torshälla, October 27th, 2022.
This information is such information that Stille AB is obliged to disclose according to the EU’s market abuse regulation. The information was, through the agency of the contact person, rendered for publication on October 27th, 2022, kl. 08.00 (CET).
For more information, please contact:
Hanna Ernestam Wilkman
CEO and President
+46 (0)72 402 10 88 | [email protected]
Stille AB (publ) publ) develops, manufactures and markets medical devices for surgeons across the world. Stille was founded in 1841 and is one of the world’s oldest medical device companies. Stille’s main business areas are surgical instruments and c-arm tables. Stille’s surgical instruments are mostly used during different kinds of open surgery. During minimal invasive procedures. the c-arm tables imagiQ2 and Medstone are key products. The company has a strong brand and products of a renowned high-quality. The share is listed on First North Growth Market under the acronym “STIL” with Eminova AB as Certified Adviser, Eminova Fondkommission AB, + 46 8 684 211 10, [email protected] For more information, visit www.stille.se.
Studie med gentestet Prostatype® publicerat i ledande internationell tidskrift
Studien som genomförts av ett forskningsteam på Akademiska sjukhuset i Uppsala under ledning av docent och överläkare Michael Häggman visar att gentestet Prostatype® korrekt bedömer prostatacancertumörens aggressivitet när man jämför genuttryck från vävnadsprover, så kallade biopsier, med ”fac...
ViroGates announces its Annual Report 2022: Growing revenue by 33% and more than tripling the customer base in clinical routine
BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, announces its Annual Report for the period 1 January – 31 December 2022, as approved today by the company’s Board of Directors....
AegirBio AB: Atlas Special Opportunities, LLC calls for partial conversion of outstanding convertible bonds to a nominal amount of MSEK 10.00
On 20 December 2022 AegirBio AB (“AegirBio” or the “Company”) announced that the Company had agreed on a convertible financing agreement with Atlas Special Opportunities, LLC (“Atlas”) regarding convertible bonds amounting to MSEK 55.00 (the “Convertible Bonds”) with attached warrants. On 20Ja...
AegirBio AB: Atlas Special Opportunities, LLC påkallar partiell konvertering av utestående konvertibler till ett nominellt belopp om 10,00 MSEK
Den 20 december 2022 meddelade AegirBio AB (”AegirBio” eller ”Bolaget”) att Bolaget avtalat om en konvertibelfinansiering med Atlas Special Opportunities, LLC (”Atlas”) avseende konvertibler om 55,00MSEK (”Konvertiblerna”) med vidhängande teckningsoptioner. Bolagsstämman beslutade den 20...